Kane BiotechKNBIF Return-on-Tangible-Asset is -167.32% as of Mar. 2026. The stock has 6 warning signs investors should review. Among 1,420 Biotechnology companies, Kane Biotech ranks worse than 78.87% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Kane Biotech's annualizedNet Income for the quarter that ended in Mar. 2026 was $-2.08 Mil. Kane Biotech's average total tangible assets for the quarter that ended in Mar. 2026 was $1.25 Mil. Therefore, Kane Biotech's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was -167.32%.
The historical rank and industry rank for Kane Biotech's Return-on-Tangible-Asset or its related term are showing as below:
KNBIF'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -332.77 Med: -111.16 Max: 176.6
Current: -100.45
During the past 13 years, Kane Biotech's highest Return-on-Tangible-Asset was 176.60%. The lowest was -332.77%. And the median was -111.16%.
KNBIF's Return-on-Tangible-Asset is ranked worse than 78.87% of 1420
companies
in the Biotechnology industry
Industry Median: -35.915
vs KNBIF: -100.45
Kane Biotech (OTCPK:KNBIF) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Kane Biotech Return-on-Tangible-Asset Related Terms
Kane Biotech Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Kane Biotech's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
KNBIF vs VRTX, REGN, ALNY: Return-on-Tangible-Asset Comparison
For the Biotechnology subindustry, Kane Biotech's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kane Biotech Return-on-Tangible-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Kane Biotech's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Kane Biotech's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of -167.32% mean?
Kane Biotech (KNBIF) has a Return-on-Tangible-Asset of -167.32% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Kane Biotech and its competitors. According to the industry distribution chart, Kane Biotech ranks #1120 out of 1420 companies in the Biotechnology industry, placing it in the top 78.9%.
Is Kane Biotech's Return-on-Tangible-Asset too high?
Kane Biotech's current Return-on-Tangible-Asset is -167.32%. Based on the distribution chart, Kane Biotech ranks #1120 out of 1420 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Kane Biotech's Return-on-Tangible-Asset compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Kane Biotech ranks #1120 out of 1420 companies for Return-on-Tangible-Asset. This places Kane Biotech in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Biotechnology company?
A good Return-on-Tangible-Asset depends on the Biotechnology industry context. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Kane Biotech and its competitors. Kane Biotech's current Return-on-Tangible-Asset is -167.32%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kane Biotech stock overvalued right now?
Kane Biotech (KNBIF) has a current Return-on-Tangible-Asset of -167.32%. The current Return-on-Tangible-Asset is -167.32%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Kane Biotech (KNBIF), the current Return-on-Tangible-Asset is -167.32% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Kane Biotech Inc is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The company has a portfolio of biotechnologies, intellectual property and products developed by its own biofilm research expertise and acquired from research institutions. The company's operating segments are animal health and human health. It derives maximum revenue from Animal health segment.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KNBIF has been successfully added to your 